| Patent Number |
Title Of Patent |
Date Issued |
| 7521241 |
Regulated gene expression in plants |
April 21, 2009 |
| A method is provided of regulating transcription in a plant cell from a DNA sequence comprising a target DNA operably linked to a coding sequence, which method comprises introducing an engineered zinc finger polypeptide in said plant cell which polypeptide binds to the target DNA and |
| 7432052 |
Method and identification of downstream mRNA ligands to FMRP and their role in fragile X syndrom |
October 7, 2008 |
| Compositions and methods for identifying and/or modulating RNA transcripts and/or genes involved in fragile X syndrome and other associated disorders are provided. In particular, RNA targets for fragile X mental retardation protein (FMRP) have been identified by a novel monoclonal an |
| 7381705 |
Inhibitors of hepatitis C virus |
June 3, 2008 |
| The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important |
| 7339039 |
Nucleic acids encoding receptor recognition factors, and methods of use thereof |
March 4, 2008 |
| Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a |
| 7033759 |
Variants of the human kappa opioid receptor gene |
April 25, 2006 |
| Provided herein are variant alleles of a gene encoding a kappa opioid receptor, along with cloning vectors for replicating such variant alleles, and expressing vectors for expressing the variant alleles to produce variant kappa opioid receptors. |
| 6395482 |
Method of determining susceptibility to schizophrenia |
May 28, 2002 |
| Variations in the DNA sequence of the human proline dehydrogenase gene (PRODH) which correlate to an increased susceptibility to, or presence of schizophrenia or a disease or disorder related thereto, such as obsessive compulsive disorder (OCD), bipolar disorder (BP), or major depressive |
| 6369030 |
Inhibitors of histone acetyltransferases (HATs) and uses thereof |
April 9, 2002 |
| Histone acetyltransferase inhibitors, especially those that are differentiate between p300 and PCAF histone acetyltransferase; also therapeutic processes comprising their administration to humans. |
| 6346605 |
Signal transducer for the TNF receptor super family, and uses thereof |
February 12, 2002 |
| A novel component of the TRAF (TNF Receptor Associated Factor) signaling complex, designated TRIP (TRAF Interacting Protein) which associates with the TNFR2 or CD30 signaling complex through its interaction with the TRAF2 protein and influences signals responsible for cell activation, ce |
| 6309853 |
Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeu |
October 30, 2001 |
| The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and to diagnostic and therapeutic uses of such modulators. In its broadest aspect, the present |
| 6297356 |
Telomere repeat binding factors and diagnostic and therapeutic use thereof |
October 2, 2001 |
| The present invention relates to a novel nucleotide sequence encoding a telomeric protein which binds a repeat region of telomeric sequences, and to the protein encoded thereby. Also included within the invention are expression vectors for the production of the telomeric protein and host |
| 6291428 |
Peptides which promote bone-forming cell attraction and adhesion |
September 18, 2001 |
| Peptides are provided with the properties of enhancing the migration and adhesion of bone-forming cells to a substrate, useful for promoting bone mineralization and osseointegration in the healing of, for example, orthopedic surgical procedures. |
| 6143566 |
Methods of performing homologous recombination based modification of nucleic acids in recombinat |
November 7, 2000 |
| A simple method for modifying genes in a recombination deficient host cell is disclosed. Such modifications include generating insertion, deletions, substitutions, and/or point mutations at any chosen site in the independent origin based cloning vector. The modified gene can be conta |
| 6139831 |
Apparatus and method for immobilizing molecules onto a substrate |
October 31, 2000 |
| Apparatus and method for immobilizing molecules, particularly biomolecules such as DNA, RNA, proteins, lipids, carbohydrates, or hormones onto a substrate such as glass or silica; patterns of immobilization can be made resulting in addressable, discrete arrays of molecules on a substrate |
| 6124118 |
Receptor recognition factors, protein sequences and methods of use thereof |
September 26, 2000 |
| Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a |
| 6106844 |
Immunomodulatory peptides of vespid antigen 5 |
August 22, 2000 |
| The present invention is directed to immunogenic peptides from vespid antigen 5. These immunogenic peptides can be used in immunotherapy for vespid venom allergic individuals. The present invention is thus directed to T cell epitopes of vespid antigen 5 that can anergize T cell responses |
| 6057129 |
Clock gene and methods of use thereof |
May 2, 2000 |
| The present invention provides isolated nucleic acids and/or recombinant DNA molecules that encode the clock protein DOUBLETIME. The present invention further provides both isolated and/or recombinant DOUBLETIME. In addition, the present invention provides antibodies to DOUBLETIME. Metho |
| 6022740 |
SH3 kinase domain associated protein, a signalling domain therein, nucleic acids encoding the pr |
February 8, 2000 |
| The present invention relates to regulation and control of cellular processes by SH3-domain binding proteins, by putative signalling domains of such proteins, ligands of the signalling domain, and diagnosis and therapy based on the activity of such proteins, signalling domains, and l |
| 6020166 |
Nucleic acid encoding an altered telomere repeat binding factor 2 |
February 1, 2000 |
| The present invention provides an isolated altered vertebrate telomere repeat binding factor (A-TRFs). Also included are the corresponding nucleic acids that encode the A-TRFs of the present invention, as well as the heterodimers formed by the association of an A-TRF with a TRF. In a |
| 6015560 |
Antibody recognizing endothelial cell ligand for leukocyte CR3 |
January 18, 2000 |
| Peptides which will inhibit the reaction between the RGD tripeptide of FHA and the integrin receptors of endothelial cells and their utility as therapeutic agents are described. |
| 6013621 |
Method of treating psychosis and/or hyperactivity |
January 11, 2000 |
| The present invention discloses the bidirectional regulation of DARPP-32 phosphorylation by dopamine and dopamine D1 and D2 receptors. This disclosure leads to new methodology in the treatment of schizophrenia and related disorders. In addition, the present invention provides methods for |
| 6013475 |
Nucleic acids encoding receptor recognition factors and methods of use thereof |
January 11, 2000 |
| Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a |
| 5863734 |
Method of treatment for obsessive-compulsive disorder |
January 26, 1999 |
| Methods of identifying patients having a susceptibility to obsessive-compulsive disorder resultant from a reduced level of Catechol-O-methyltransferase (COMT) are described. Therapies, utilizing COMT or COMT agonists, or dopamine antagonists in combination therewith, are also envisio |
| 5652352 |
Afamin: a human serum albumin-like gene |
July 29, 1997 |
| The invention relates to a novel human serum protein and nucleic acid referred to as AFM, which has one or more activities in common with human serum albumin, human a-fetoprotein, or human vitamin D binding protein and which has an apparent molecular weight by SDS-PAGE of 87 kd; variants |
